Dutasteride لـ الثعلبة الأندروجينية

References

1. [1] Aditya K Gupta et al.. Int J Dermatol. 2026. Is the Safety of Finasteride Correlated With Its Route of Administration: Topical Versus Oral? A Pharmacovigilance Study With Data From … doi:10.1111/ijd.17957 PubMed
2. [2] Aditya K Gupta et al.. J Dermatolog Treat. 2026. Oral finasteride use and sexual adverse events: signal detection from disproportionality analyses of data from the United States Food and … doi:10.1080/09546634.2025.2611703 PubMed
3. [3] Jacob Beer et al.. Dermatol Surg. 2026. Injectable Therapy for Androgenetic Alopecia: A Systematic Review. doi:10.1097/DSS.0000000000004999 PubMed
4. [4] Nicolò Rivetti. Skin Appendage Disord. 2026. Scalp Microinfusion with Dutasteride Using the MMP® Technique for Male Androgenetic Alopecia: A 12-Month Real-World Observational Case Series. doi:10.1159/000550858 PubMed
5. [5] Caitlin A Kearney et al.. Am J Clin Dermatol. 2026. Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments. doi:10.1007/s40257-026-01009-2 PubMed
6. [6] Daniel Ramos-Rodriguez et al.. Dermatol Ther (Heidelb). 2026. Characterization and Management of Androgenetic Alopecia in Transgender and Gender-Diverse Individuals: A Narrative Review. doi:10.1007/s13555-026-01735-9 PubMed
7. [7] Jayanaraian F M Andrade et al.. Expert Opin Drug Deliv. 2025. An update on nanocarriers for follicular-targeted drug delivery for androgenetic alopecia topical treatment. doi:10.1080/17425247.2025.2457950 PubMed
8. [8] Ilmari Saarinen et al.. Br J Surg. 2025. Nutritional deficiencies after sleeve gastrectomy and Roux-en-Y gastric bypass at 10 years: secondary analysis of the SLEEVEPASS randomized clinical trial. doi:10.1093/bjs/znaf132 PubMed
9. [9] Aditya K Gupta et al.. PLoS One. 2025. Epidemiological landscape of androgenetic alopecia in the US: An All of Us cross-sectional study. doi:10.1371/journal.pone.0319040 PubMed
10. [10] Jayanaraian F M Andrade et al.. Ther Deliv. 2025. Topical dutasteride for androgenic alopecia: current state and prospects. doi:10.1080/20415990.2024.2437973 PubMed
11. [11] Álvaro Vergara A Nieto et al.. Curr Nutr Rep. 2025. Are there Effective Vegan-Friendly Supplements for Optimizing Health and Sports Performance? a Narrative Review. doi:10.1007/s13668-025-00633-4 PubMed
12. [12] Sara Ahmed Galal et al.. Lasers Med Sci. 2025. Comparative study between fractional CO2 laser alone versus fractional CO2 laser combined with topical dutasteride in treatment of male androgenic … doi:10.1007/s10103-024-04269-8 PubMed
13. [13] Aditya K Gupta et al.. Expert Opin Pharmacother. 2025. Efficacy and safety of dutasteride in the treatment of alopecia: a comprehensive review. doi:10.1080/14656566.2025.2461169 PubMed
14. [14] Lili Legiawati et al.. Arch Dermatol Res. 2025. Hair regeneration in androgenetic alopecia using secretome of adipose-derived stem cells (ADSC) and minoxidil: a comparative study of three groups. doi:10.1007/s00403-025-04006-3 PubMed
15. [15] Guilherme Kuceki et al.. JAAD Int. 2025. Enhanced hair regrowth with five monthly sessions of minoxidil-dutasteride-copper peptides tattooing for androgenetic alopecia assessed by artificial intelligence and blinded … doi:10.1016/j.jdin.2025.01.012 PubMed
16. [16] Aditya K Gupta et al.. J Cosmet Dermatol. 2025. Finasteride Use: Evaluation of Depression and Suicide Risk. doi:10.1111/jocd.70102 PubMed
17. [17] Varalee Sereepanpanich et al.. JAAD Int. 2025. Efficacy and safety of twice- or thrice-weekly dutasteride versus daily finasteride in men with androgenetic alopecia: A randomized, investigator-blinded, active-controlled, … doi:10.1016/j.jdin.2025.08.009 PubMed
18. [18] Jayanaraian F M Andrade et al.. Pharmaceutics. 2025. Development of Ethosomes for the Topical Treatment of Androgenic Alopecia: Ethanol Effect on Dutasteride Targeting to the Hair Follicles. doi:10.3390/pharmaceutics17060786 PubMed
19. [19] Laxmi Iyengar et al.. Aust Prescr. 2025. Male and female pattern hair loss. doi:10.18773/austprescr.2025.020 PubMed
20. [20] Ian Landells et al.. J Cutan Med Surg. 2025. A Canadian Consensus on Androgenetic Alopecia: Approach and Management. doi:10.1177/12034754251368849 PubMed
21. [21] Behnam Hasannejad-Asl et al.. Front Bioinform. 2025. Computational drug discovery of potential 5α-reductase phytochemical inhibitors and hair growth promotion using in silico techniques. doi:10.3389/fbinf.2025.1570101 PubMed
22. [22] Ambika Nohria et al.. J Am Acad Dermatol. 2025. Treatment of androgenetic alopecia with low-dose oral minoxidil monotherapy compared with combination therapy with dutasteride or finasteride. doi:10.1016/j.jaad.2025.01.067 PubMed
23. [23] Aditya K Gupta et al.. J Cosmet Dermatol. 2025. Comparative Efficacy of Minoxidil and 5-Alpha Reductase Inhibitors Monotherapy for Male Pattern Hair Loss: Network Meta-Analysis Study of Current Empirical … doi:10.1111/jocd.70320 PubMed
24. [24] Young Jae Kim et al.. Clin Exp Reprod Med. 2025. Long-term use of dutasteride to treat androgenic alopecia in young men may lead to persistent abnormalities in semen parameters. doi:10.5653/cerm.2024.07675 PubMed
25. [25] Subin Lee et al.. Ann Dermatol. 2025. Efficacy and Safety of Low-Dose (0.2 mg) Dutasteride for Male Androgenic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III … doi:10.5021/ad.25.048 PubMed
26. [26] Yudie Lv et al.. Int J Biol Macromol. 2025. Bifunctional sodium hyaluronate microneedle patches integrating 5α-reductase and ROS regulation for boosted hair regeneration. doi:10.1016/j.ijbiomac.2025.146316 PubMed
27. [27] Megha Chandrashekhar et al.. Int J Trichology. 2025. Paradoxical Nonscarring Alopecia Following Mesotherapy with Dutasteride: A Case Series. doi:10.4103/ijt.ijt_98_24 PubMed
28. [28] Nghiem H Nguyen et al.. J Plast Reconstr Aesthet Surg. 2025. Estrogen hormone therapy stabilizes lateral hairline in transfeminine patients: Implications for facial feminization surgery. doi:10.1016/j.bjps.2024.07.044 PubMed
29. [29] Luciana Gasques et al.. Skin Appendage Disord. 2025. Dutasteride Infusion in Male Androgenetic Alopecia Using a Novel Drug Delivery Technique: MMP®. doi:10.1159/000546871 PubMed
30. [30] Ana Melián-Olivera et al.. J Clin Med. 2025. Frontal Fibrosing Alopecia in Men: A Review of the Literature. doi:10.3390/jcm14061914 PubMed
31. [31] Miquel Martínez-Navarrete et al.. Eur J Pharm Biopharm. 2025. Enhanced ex vivo skin retention of bicalutamide using a nano-in-micro composite: Drug-loaded lipid vesicles in a dissolving microarray patch. doi:10.1016/j.ejpb.2025.114728 PubMed
32. [32] Stephano Cedirian et al.. Dermatol Ther (Heidelb). 2025. Efficacy of Skin Patting and Iontophoresis with Dutasteride Gel in Male and Menopausal Female Androgenetic Alopecia: A Pilot Study. doi:10.1007/s13555-025-01532-w PubMed
33. [33] Zachary Neubauer et al.. J Am Acad Dermatol. 2025. No increased risk of mood disorders in male androgenetic alopecia patients treated with dutasteride and finasteride: A retrospective cohort database … doi:10.1016/j.jaad.2025.03.068 PubMed
34. [34] Jung-Won Shin et al.. Ann Dermatol. 2025. Updates in Treatment for Androgenetic Alopecia. doi:10.5021/ad.25.042 PubMed
35. [35] Anurak Muangsanguan et al.. Foods. 2025. Anti-Hair Loss Potential of Perilla Seed Extracts: In Vitro Molecular Insights from Supercritical Fluid Extraction. doi:10.3390/foods14152583 PubMed
36. [36] Baltazar Sanabria et al.. J Eur Acad Dermatol Venereol. 2025. Monthly versus quarterly dutasteride mesotherapy for male androgenetic alopecia: A randomized trial. doi:10.1111/jdv.70237 PubMed
37. [37] Aditya K Gupta et al.. J Cosmet Dermatol. 2025. Relative Efficacy of Conventional Monotherapies and Select Nonconventional, Over-the-Counter Products for Male Androgenetic Alopecia: A Network Meta-Analysis Study. doi:10.1111/jocd.70483 PubMed
38. [38] Veerendra Kumar Panuganti et al.. Cureus. 2025. A Randomized, Double-Blind, Placebo and Active Controlled Phase II Study to Evaluate the Safety and Efficacy of Novel Dutasteride Topical … doi:10.7759/cureus.89309 PubMed
39. [39] Adal Mena-García et al.. Molecules. 2025. Kyoh® Rocket Leaf Extract Regulates Proliferation and VEGF and FGF7 Expression in Human Dermal Follicle Papilla Cells. doi:10.3390/molecules30071489 PubMed
40. [40] Abdullah Almeziny et al.. J Cosmet Dermatol. 2025. Effectiveness and Safety of Intralesional Dutasteride in Patients With Androgenic Alopecia: A Systematic Review and Meta-Analysis. doi:10.1111/jocd.70560 PubMed
41. [41] Zachary Neubauer et al.. Int J Dermatol. 2025. Similar Risk of Sexual Dysfunction in Androgenetic Alopecia Patients Treated With Dutasteride vs. Finasteride: A Retrospective Cohort Database Study. doi:10.1111/ijd.17887 PubMed
42. [42] Barbara Owecka et al.. Biomedicines. 2024. The Hormonal Background of Hair Loss in Non-Scarring Alopecias. doi:10.3390/biomedicines12030513 PubMed
43. [43] Yunbu Ding et al.. Dermatology. 2024. Dutasteride for the Treatment of Androgenetic Alopecia: An Updated Review. doi:10.1159/000541395 PubMed
44. [44] S Morteza Seyed Jafari et al.. J Clin Med. 2024. Safety of Antiandrogens for the Treatment of Female Androgenetic Alopecia with Respect to Gynecologic Malignancies. doi:10.3390/jcm13113052 PubMed
45. [45] Amanda Rosenthal et al.. J Cosmet Laser Ther. 2024. Management of androgenic alopecia: a systematic review of the literature. doi:10.1080/14764172.2024.2362126 PubMed
46. [46] Alessandro Uleri et al.. Eur Urol Focus. 2024. Association of 5α-Reductase Inhibitors with Depression and Suicide: A Mini Systematic Review and Meta-analysis. doi:10.1016/j.euf.2024.04.009 PubMed
47. [47] Ratchathorn Panchaprateep. Facial Plast Surg. 2024. Medical Treatment for Androgenetic Alopecia. doi:10.1055/a-2196-4713 PubMed
48. [48] Aditya K Gupta et al.. J Cosmet Dermatol. 2024. The impact of monotherapies for male androgenetic alopecia: A network meta-analysis study. doi:10.1111/jocd.16362 PubMed
49. [49] Aditya K Gupta et al.. Expert Opin Emerg Drugs. 2024. Emerging and traditional 5-α reductase inhibitors and androgen receptor antagonists for male androgenetic alopecia. doi:10.1080/14728214.2024.2346590 PubMed
50. [50] Xuehua Ruan et al.. Environ Health. 2024. Maternal multivitamin supplementation mitigates the risk of fetal congenital heart disease associated with high indoor total volatile organic compounds exposure … doi:10.1186/s12940-024-01150-7 PubMed
51. [51] Aditya K Gupta et al.. Expert Opin Pharmacother. 2024. Efficacy and safety of low-dose oral minoxidil in the management of androgenetic alopecia. doi:10.1080/14656566.2024.2314087 PubMed
52. [52] Aditya K Gupta et al.. J Cosmet Dermatol. 2024. The relative effect of monotherapy with 5-alpha reductase inhibitors and minoxidil for female pattern hair loss: A network meta-analysis study. doi:10.1111/jocd.15910 PubMed
53. [53] Kyle C Lauck et al.. J Am Acad Dermatol. 2024. Sexual dysfunction with 5-alpha-reductase inhibitor therapy for androgenetic alopecia: A global propensity score matched retrospective cohort study. doi:10.1016/j.jaad.2024.03.019 PubMed
54. [54] Jayanaraian F M Andrade et al.. Pharmaceutics. 2024. Evaluation of Dutasteride-Loaded Liposomes and Transfersomes for Follicular-Targeting for Androgenic Alopecia Topical Treatment. doi:10.3390/pharmaceutics16121524 PubMed
55. [55] Mahboob Alam et al.. Pharm Nanotechnol. 2024. Development and Evaluation of Dutasteride Nanoemulgel for the Topical Delivery against Androgenic Alopecia. doi:10.2174/0122117385269151231031161411 PubMed
56. [56] Almuntsrbellah Almudimeegh et al.. Dermatol Reports. 2024. Comparison between dutasteride and finasteride in hair regrowth and reversal of miniaturization in male and female androgenetic alopecia: a systematic … doi:10.4081/dr.2024.9909 PubMed
57. [57] Deesha D Desai et al.. Arch Dermatol Res. 2024. Comparative analysis of low-dose oral minoxidil with spironolactone versus finasteride or dutasteride in female androgenetic alopecia management. doi:10.1007/s00403-024-03361-x PubMed
58. [58] Sangmin Choi et al.. J Dermatol. 2024. Long-term efficacy and safety of dutasteride 0.5 mg in Korean men with androgenetic alopecia: 5-year data demonstrating clinical improvement with … doi:10.1111/1346-8138.17138 PubMed
59. [59] Ambika Nohria et al.. JAAD Case Rep. 2024. Outcomes of androgenetic alopecia treated with dutasteride mesotherapy: A case series. doi:10.1016/j.jdcr.2024.09.024 PubMed
60. [60] Vaibhav Kumar et al.. J Cosmet Dermatol. 2024. "Effectiveness of minimally invasive injectable modalities in the management of androgenetic alopecia among adults-A systematic review". doi:10.1111/jocd.16493 PubMed
61. [61] Paula Hallam. Nestle Nutr Inst Workshop Ser. 2024. Nutrition Challenges and Opportunities When Shifting to Plant-Based Diets. doi:10.1159/000540147 PubMed
62. [62] David Saceda-Corralo et al.. Am J Clin Dermatol. 2023. What's New in Therapy for Male Androgenetic Alopecia? doi:10.1007/s40257-022-00730-y PubMed
63. [63] Julia L Gao et al.. J Am Acad Dermatol. 2023. Androgenetic alopecia in transgender and gender diverse populations: A review of therapeutics. doi:10.1016/j.jaad.2021.08.067 PubMed
64. [64] Mariana Escamilla-Cruz et al.. Dermatol Ther (Heidelb). 2023. Use of 5-Alpha Reductase Inhibitors in Dermatology: A Narrative Review. doi:10.1007/s13555-023-00974-4 PubMed
65. [65] Parth S Bajoria et al.. Cureus. 2023. Comparing Current Therapeutic Modalities of Androgenic Alopecia: A Literature Review of Clinical Trials. doi:10.7759/cureus.42768 PubMed
66. [66] Ashling Courtney et al.. Expert Opin Pharmacother. 2023. Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia. doi:10.1080/14656566.2023.2280630 PubMed
67. [67] Yoshitaka Hobo et al.. Clin Chim Acta. 2023. Evaluation of the therapeutic effects of AGA drugs by measuring finasteride, dutasteride, and dihydrotestosterone in hair. doi:10.1016/j.cca.2023.117456 PubMed
68. [68] Celina Dubin et al.. JAAD Case Rep. 2023. Hair regrowth in endocrine therapy alopecia with dutasteride treatment in woman with estrogen positive breast cancer. doi:10.1016/j.jdcr.2023.02.021 PubMed
69. [69] Sara D Ragi et al.. JAAD Int. 2023. Evaluation of hair regrowth after minoxidil and dutasteride tattooing in men with androgenetic alopecia. doi:10.1016/j.jdin.2023.04.011 PubMed
70. [70] Francisco José Rodríguez-Cuadrado et al.. Eur J Dermatol. 2023. Mesotherapy with dutasteride for androgenetic alopecia: a concise review of the literature. doi:10.1684/ejd.2023.4443 PubMed
71. [71] Monica Păun et al.. Medicina (Kaunas). 2023. Epidemiologic Study of Gene Distribution in Romanian and Brazilian Patients with Non-Cicatricial Alopecia. doi:10.3390/medicina59091654 PubMed
72. [72] Lina Alhanshali et al.. Dermatol Surg. 2023. Intradermal Delivery of Alopecia Therapeutics: Current State and Future Prospects. doi:10.1097/DSS.0000000000003866 PubMed
73. [73] Aditya K Gupta et al.. J Dermatolog Treat. 2022. Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia. doi:10.1080/09546634.2022.2109567 PubMed
74. [74] Aditya K Gupta et al.. JAMA Dermatol. 2022. Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis. doi:10.1001/jamadermatol.2021.5743 PubMed
75. [75] Warintorn Ruksiriwanich et al.. Plants (Basel). 2022. Phytochemical Constitution, Anti-Inflammation, Anti-Androgen, and Hair Growth-Promoting Potential of Shallot (Allium ascalonicum L.) Extract. doi:10.3390/plants11111499 PubMed
76. [76] Aditya K Gupta et al.. J Dermatolog Treat. 2022. Efficacy of non-surgical treatments for androgenetic alopecia in men and women: a systematic review with network meta-analyses, and an assessment … doi:10.1080/09546634.2020.1749547 PubMed
77. [77] Miguel Garcia-Argibay et al.. JAMA Netw Open. 2022. Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide. doi:10.1001/jamanetworkopen.2022.48135 PubMed
78. [78] David Saceda-Corralo et al.. J Drugs Dermatol. 2022. Mesotherapy With Dutasteride for Androgenetic Alopecia: A Retrospective Study in Real Clinical Practice. doi:10.36849/JDD.6610 PubMed
79. [79] Silvia Tampucci et al.. Pharmaceutics. 2022. Nanostructured Drug Delivery Systems for Targeting 5-α-Reductase Inhibitors to the Hair Follicle. doi:10.3390/pharmaceutics14020286 PubMed
80. [80] Gwang-Seong Choi et al.. Ann Dermatol. 2022. Long-Term Effectiveness and Safety of Dutasteride versus Finasteride in Patients with Male Androgenic Alopecia in South Korea: A Multicentre Chart … doi:10.5021/ad.22.027 PubMed
81. [81] Daniel Fernandes Melo et al.. Dermatol Ther. 2022. Frontal edema due to mesotherapy for androgenetic alopecia: A case series. doi:10.1111/dth.15247 PubMed
82. [82] Peter R Feldman et al.. Front Med (Lausanne). 2022. Hair regrowth treatment efficacy and resistance in androgenetic alopecia: A systematic review and continuous Bayesian network meta-analysis. doi:10.3389/fmed.2022.998623 PubMed
83. [83] E Sánchez-Meza et al.. J Eur Acad Dermatol Venereol. 2022. Microneedling plus topical dutasteride solution for androgenetic alopecia: a randomized placebo-controlled study. doi:10.1111/jdv.18285 PubMed
84. [84] Xiangru Chen et al.. Front Bioeng Biotechnol. 2022. Bioengineered polyester nanoparticles for the synergistic treatment of androgenic alopecia via the suppression of 5α-reductase and knockdown of androgen receptor. doi:10.3389/fbioe.2022.1033987 PubMed
85. [85] Aye Chan Khine Lin et al.. Sci Rep. 2022. Caffeic acid N-[3,5-bis(trifluoromethyl)phenyl] amide as a non-steroidal inhibitor for steroid 5α-reductase type 1 using a human keratinocyte cell-based assay and … doi:10.1038/s41598-022-25335-7 PubMed
86. [86] Belén Proaño et al.. Biomedicines. 2022. Is Dutasteride a Therapeutic Alternative for Amyotrophic Lateral Sclerosis? doi:10.3390/biomedicines10092084 PubMed
87. [87] Giulia Gava et al.. J Sex Med. 2021. A Randomized Double-Blind Placebo-Controlled Pilot Trial on the Effects of Testosterone Undecanoate Plus Dutasteride or Placebo on Muscle Strength, Body … doi:10.1016/j.jsxm.2020.12.015 PubMed
88. [88] Matthew B Harrell et al.. World J Urol. 2021. An evaluation of the federal adverse events reporting system data on adverse effects of 5-alpha reductase inhibitors. doi:10.1007/s00345-020-03314-9 PubMed
89. [89] Min-Jeong Kang et al.. J Am Acad Dermatol. 2021. 5α-Reductase inhibitors in men aged 50 years or older with androgenetic alopecia: A retrospective study. doi:10.1016/j.jaad.2020.04.051 PubMed
90. [90] Abdulmaged M Traish. Fertil Steril. 2020. Post-finasteride syndrome: a surmountable challenge for clinicians. doi:10.1016/j.fertnstert.2019.11.030 PubMed
91. [91] Silvia Diviccaro et al.. Neurobiol Stress. 2020. Post-finasteride syndrome: An emerging clinical problem. doi:10.1016/j.ynstr.2019.100209 PubMed
92. [92] Wimolsiri Iamsumang et al.. Drug Des Devel Ther. 2020. Finasteride and Its Potential for the Treatment of Female Pattern Hair Loss: Evidence to Date. doi:10.2147/DDDT.S240615 PubMed
93. [93] Rachita Dhurat et al.. Dermatol Ther. 2020. 5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety. doi:10.1111/dth.13379 PubMed
94. [94] Abdulmaged M Traish. World J Mens Health. 2020. Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It's Time to Sound the Alarm. doi:10.5534/wjmh.200012 PubMed
95. [95] Julie Robitaille et al.. Gen Comp Endocrinol. 2020. Consequences of steroid-5α-reductase deficiency and inhibition in vertebrates. doi:10.1016/j.ygcen.2020.113400 PubMed
96. [96] Maira Elizabeth Herz-Ruelas et al.. Skin Appendage Disord. 2020. Efficacy of Intralesional and Oral Dutasteride in the Treatment of Androgenetic Alopecia: A Systematic Review. doi:10.1159/000510697 PubMed
97. [97] Sergio Vañó-Galván et al.. Dermatol Ther. 2020. Effectiveness and safety of oral dutasteride for male androgenetic alopecia in real clinical practice: A descriptive monocentric study. doi:10.1111/dth.13182 PubMed
98. [98] Tymon Tai et al.. Facial Plast Surg Clin North Am. 2020. Physiology and Medical Treatments for Alopecia. doi:10.1016/j.fsc.2020.01.004 PubMed
99. [99] Norhayati Mohamed Noor et al.. Pharmaceutics. 2020. In Vitro Performance of Dutasteride-Nanostructured Lipid Carriers Coated with Lauric Acid-Chitosan Oligomer for Dermal Delivery. doi:10.3390/pharmaceutics12100994 PubMed
100. [100] Solmaz Asnaashari et al.. Altern Ther Health Med. 2020. Herbal Medicines For Treatment of Androgenic Alopecia. PubMed
101. [101] Tuo Deng et al.. Urol J. 2020. Association Between 5-Alpha Reductase Inhibitor Use and The Risk of Depression: A Meta-Analysis. doi:10.22037/uj.v16i7.5866 PubMed
102. [102] Cristina Pindado-Ortega et al.. Skin Appendage Disord. 2020. Prescribing Habits for Androgenic Alopecia among Dermatologists in Spain in 2019-2020: A Cross-Sectional Study. doi:10.1159/000509063 PubMed
103. [103] Bo Kyu Choi et al.. Yonsei Med J. 2020. Cerebral Venous Sinus Thrombosis Associated with Dutasteride Use. doi:10.3349/ymj.2020.61.6.553 PubMed
104. [104] L Reguero-Del Cura et al.. Actas Dermosifiliogr (Engl Ed). 2020. RF-Mesotherapy With Dutasteride: A Future Alternative Treatment for Androgenetic Alopecia. doi:10.1016/j.ad.2018.10.030 PubMed
105. [105] Abdullah Gul et al.. Arch Esp Urol. 2020. Impact of dutasteride on spermatogenesis and oxidative status in rats. PubMed
106. [106] Amanda Bienenfeld et al.. J Am Acad Dermatol. 2019. Androgens in women: Androgen-mediated skin disease and patient evaluation. doi:10.1016/j.jaad.2018.08.062 PubMed
107. [107] Solam Lee et al.. Acta Derm Venereol. 2019. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis. doi:10.2340/00015555-3035 PubMed
108. [108] Zhongbao Zhou et al.. Clin Interv Aging. 2019. The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis. doi:10.2147/CIA.S192435 PubMed
109. [109] Sarah Azarchi et al.. J Am Acad Dermatol. 2019. Androgens in women: Hormone-modulating therapies for skin disease. doi:10.1016/j.jaad.2018.08.061 PubMed
110. [110] Enis Rauf Coskuner et al.. Sex Med Rev. 2019. Sexual Problems of Men With Androgenic Alopecia Treated With 5-Alpha Reductase Inhibitors. doi:10.1016/j.sxmr.2018.07.003 PubMed
111. [111] Radosław B Maksym et al.. Aging Male. 2019. Post-finasteride syndrome - does it really exist? doi:10.1080/13685538.2018.1548589 PubMed
112. [112] Jukkarin Srivilai et al.. Assay Drug Dev Technol. 2019. Discovery of Natural Steroid 5 Alpha-Reductase Inhibitors. doi:10.1089/adt.2018.870 PubMed
113. [113] Seong-Wook Seo et al.. Pharmaceutics. 2019. In Vitro and In Vivo Assessment of Metabolic Drug Interaction Potential of Dutasteride with Ketoconazole. doi:10.3390/pharmaceutics11120673 PubMed
114. [114] Buse Güler et al.. J Perinat Med. 2019. An investigation of vitamin and mineral supplement recommendation among first-trimester pregnancies. doi:10.1515/jpm-2019-0178 PubMed
115. [115] Karolina Kozicka et al.. Pol Merkur Lekarski. 2019. Methods of treatment patients with androgenetic alopecia based on reference of Department of Dermatology in Cracow. PubMed
116. [116] Arang Rhie et al.. PLoS One. 2019. Genetic variations associated with response to dutasteride in the treatment of male subjects with androgenetic alopecia. doi:10.1371/journal.pone.0222533 PubMed
117. [117] V Kanti et al.. J Eur Acad Dermatol Venereol. 2018. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version. doi:10.1111/jdv.14624 PubMed
118. [118] A K Gupta et al.. J Eur Acad Dermatol Venereol. 2018. Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis. doi:10.1111/jdv.15081 PubMed
119. [119] Motomu Manabe et al.. J Dermatol. 2018. Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss, 2017 version. doi:10.1111/1346-8138.14470 PubMed
120. [120] Ion G Motofei et al.. Expert Opin Drug Saf. 2018. Androgenetic alopecia; drug safety and therapeutic strategies. doi:10.1080/14740338.2018.1430765 PubMed
121. [121] Tsen-Fang Tsai et al.. J Dermatol. 2018. Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia. doi:10.1111/1346-8138.14329 PubMed
122. [122] C Pindado-Ortega et al.. Actas Dermosifiliogr (Engl Ed). 2018. Prescribing Habits for Androgenic Alopecia Among Dermatologists in Spain in 2017: A Cross-Sectional Study. doi:10.1016/j.ad.2018.02.006 PubMed
123. [123] Sujit J S Shanshanwal et al.. Indian J Dermatol Venereol Leprol. 2017. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled … doi:10.4103/0378-6323.188652 PubMed
124. [124] Tasleem Arif et al.. Curr Clin Pharmacol. 2017. Dutasteride in Androgenetic Alopecia: An Update. doi:10.2174/1574884712666170310111125 PubMed
125. [125] Raymond M Fertig et al.. Dermatol Online J. 2017. Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review. PubMed
126. [126] David Saceda-Corralo et al.. Int J Trichology. 2017. Mesotherapy with Dutasteride in the Treatment of Androgenetic Alopecia. doi:10.4103/ijt.ijt_73_16 PubMed
127. [127] Abdulmaged M Traish. Adv Exp Med Biol. 2017. Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men. doi:10.1007/978-3-319-70178-3_22 PubMed
128. [128] S Vañó-Galván et al.. Actas Dermosifiliogr. 2017. New Treatments for Hair Loss. doi:10.1016/j.ad.2016.11.010 PubMed
129. [129] Ho Won Kang et al.. J Urol. 2017. Change in Prostate Specific Antigen Concentration in Men with Prostate Specific Antigen Less than 2.5 ng/ml Taking Low Dose Finasteride … doi:10.1016/j.juro.2017.07.075 PubMed
130. [130] Ph Paquet et al.. Rev Med Liege. 2017. [What is the value of low-energie lasers in the treatment of androgenetic alopecia ?]. PubMed
131. [131] Yuichiro Tsunemi et al.. J Dermatol. 2016. Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia. doi:10.1111/1346-8138.13310 PubMed
132. [132] Gwang Seong Choi et al.. Ann Dermatol. 2016. Safety and Tolerability of the Dual 5-Alpha Reductase Inhibitor Dutasteride in the Treatment of Androgenetic Alopecia. doi:10.5021/ad.2016.28.4.444 PubMed
133. [133] Jukkarin Srivilai et al.. Steroids. 2016. A new label-free screen for steroid 5α-reductase inhibitors using LC-MS. doi:10.1016/j.steroids.2016.10.007 PubMed
134. [134] Esther J van Zuuren et al.. Cochrane Database Syst Rev. 2016. Interventions for female pattern hair loss. doi:10.1002/14651858.CD007628.pub4 PubMed
135. [135] Anita K Gupta et al.. Indian J Pharmacol. 2016. Atypical post-finasteride syndrome: A pharmacological riddle. doi:10.4103/0253-7613.182898 PubMed
136. [136] Abdulmaged M Traish et al.. Rev Endocr Metab Disord. 2015. Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know? doi:10.1007/s11154-015-9319-y PubMed
137. [137] Dimitrios Ioannides et al.. Curr Probl Dermatol. 2015. Female pattern hair loss. doi:10.1159/000369404 PubMed
138. [138] Walter Gubelin Harcha et al.. J Am Acad Dermatol. 2014. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride … doi:10.1016/j.jaad.2013.10.049 PubMed
139. [139] Aditya K Gupta et al.. J Dermatolog Treat. 2014. The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride. doi:10.3109/09546634.2013.813011 PubMed
140. [140] Leyre Falto-Aizpurua et al.. Expert Opin Emerg Drugs. 2014. Emerging treatments in alopecia. doi:10.1517/14728214.2014.974550 PubMed
141. [141] Jae Yoon Jung et al.. Int J Dermatol. 2014. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride. doi:10.1111/ijd.12060 PubMed
142. [142] Ids H Boersma et al.. Indian J Dermatol Venereol Leprol. 2014. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia. doi:10.4103/0378-6323.144162 PubMed
143. [143] Elizabeth Yim et al.. Curr Opin Endocrinol Diabetes Obes. 2014. 5α-Reductase inhibitors in androgenetic alopecia. doi:10.1097/MED.0000000000000112 PubMed
144. [144] Nusrat Banka et al.. Dermatol Clin. 2013. Pattern hair loss in men: diagnosis and medical treatment. doi:10.1016/j.det.2012.08.003 PubMed
145. [145] Nattaya Lourith et al.. J Cosmet Dermatol. 2013. Hair loss and herbs for treatment. doi:10.1111/jocd.12051 PubMed
146. [146] Landon Trost et al.. Sex Med Rev. 2013. Side Effects of 5-Alpha Reductase Inhibitors: A Comprehensive Review. doi:10.1002/smrj.3 PubMed
147. [147] Aron G Nusbaum et al.. Facial Plast Surg Clin North Am. 2013. Nonsurgical therapy for hair loss. doi:10.1016/j.fsc.2013.04.003 PubMed
148. [148] Faris Azzouni et al.. J Drugs Dermatol. 2013. Role of 5α-reductase inhibitors in androgen-stimulated skin disorders. PubMed
149. [149] Hammad A Bhatti et al.. J Cosmet Dermatol. 2013. Hair restoration approaches for early onset male androgenetic alopecia. doi:10.1111/jocd.12047 PubMed
150. [150] Lauren L Levy et al.. Int J Womens Health. 2013. Female pattern alopecia: current perspectives. doi:10.2147/IJWH.S49337 PubMed
151. [151] K J McElwee et al.. Skin Therapy Lett. 2012. Promising therapies for treating and/or preventing androgenic alopecia. PubMed
152. [152] Shalender Bhasin et al.. JAMA. 2012. Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: … doi:10.1001/jama.2012.227 PubMed
153. [153] A W Rafi et al.. ISRN Dermatol. 2011. Pilot Study of 15 Patients Receiving a New Treatment Regimen for Androgenic Alopecia: The Effects of Atopy on AGA. doi:10.5402/2011/241953 PubMed
154. [154] Deepani Rathnayake et al.. Expert Opin Pharmacother. 2010. Male androgenetic alopecia. doi:10.1517/14656561003752730 PubMed
155. [155] Adel Alsantali et al.. Curr Opin Endocrinol Diabetes Obes. 2009. Androgens and hair loss. doi:10.1097/med.0b013e32832b100a PubMed
156. [156] Francisco M Camacho-Martínez. Semin Cutan Med Surg. 2009. Hair loss in women. doi:10.1016/j.sder.2009.01.001 PubMed
157. [157] Noah Scheinfeld. Dermatol Online J. 2008. A review of hormonal therapy for female pattern (androgenic) alopecia. PubMed
158. [158] Malgorzata Olszewska et al.. J Drugs Dermatol. 2005. Effective treatment of female androgenic alopecia with dutasteride. PubMed